Comparative Pharmacology
Head-to-head clinical analysis: CODOXY versus MUCINEX DM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CODOXY versus MUCINEX DM.
CODOXY vs MUCINEX DM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Oxycodone is a full opioid agonist with relative selectivity for the mu-opioid receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of oxycodone is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia. Oxycodone is combined with aspirin to provide additive analgesic effects.
Guaifenesin increases respiratory tract fluid secretion to reduce mucus viscosity; dextromethorphan acts on sigma-1 receptors and NMDA receptor antagonism to suppress cough reflex.
1-2 capsules orally every 4-6 hours as needed for pain, not to exceed 8 capsules per day. Each capsule contains 5 mg hydrocodone bitartrate and 325 mg acetaminophen.
One tablet (guaifenesin 600 mg / dextromethorphan HBr 30 mg) orally every 12 hours, not to exceed 2 tablets in 24 hours.
None Documented
None Documented
Terminal half-life is 3.5 hours in patients with normal renal function; extends to 5-8 hours in moderate renal impairment.
Guaifenesin: 1-3 hours. Dextromethorphan: 3-30 hours depending on CYP2D6 phenotype; extensive metabolizers 3-8 hours, poor metabolizers 15-30 hours.
Renal excretion of unchanged drug accounts for approximately 70% of elimination; biliary/fecal excretion accounts for 30%.
Guaifenesin: renal (primarily as inactive metabolites, <1% unchanged). Dextromethorphan: renal (as unchanged drug and metabolites, including dextrorphan). Approximately 80% eliminated in urine as metabolites.
Category C
Category C
Antitussive Combination
Expectorant/Antitussive Combination